Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the successful completion of the pivotal Phase 3 PIVOT-PO trial for tebipenem HBr, an investigational oral antibiotic intended for use in treating complicated urinary tract infections.

The Phase 3 study, conducted in collaboration with development partner GSK plc, effectively achieved its primary goal, proving that tebipenem HBr is not inferior to the intravenous antibiotic imipenem-cilastatin in treating adult hospitalized patients with cUTI. According to a press statement issued by Spero on May 28, tebipenem HBr may be the first oral carbapenem antibiotic that patients in the U.S. can get, potentially addressing an estimated 2.9 million annual cases of cUTIs.

The full trial results will be submitted to a peer-reviewed journal for publication and presentation at a later scientific convention, with Spero and GSK intending to submit the findings to the FDA in the second half of 2025.

While we acknowledge the potential of SPRO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SPRO and that has 100x upside potential, check out our report about the cheapest AI stock.

Read More: 10 Defensive Stocks Billionaire Ken Fisher Is Betting On and 10 Best Stocks to Buy According to Billionaire Steve Cohen.

Disclosure: None.